Based on the Sanara Medtech Inc stock forecast from 2 analysts, the average analyst target price for Sanara Medtech Inc is USD 47.83 over the next 12 months. Sanara Medtech Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Sanara Medtech Inc is Slightly Bearish, which is based on 3 positive signals and 4 negative signals. At the last closing, Sanara Medtech Inc’s stock price was USD 29.20. Sanara Medtech Inc’s stock price has changed by -2.89% over the past week, -11.54% over the past month and -11.54% over the last year.
No recent analyst target price found for Sanara Medtech Inc
No recent average analyst rating found for Sanara Medtech Inc
Company Overview Sanara Medtech Inc
Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. It also provides BIAKOS Antimicrobial Skin and Wound Cleanser, a patented product that contains synergistic ingredients that have been shown to impact mature biofilm microbes; BIAKOS Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing that helps against planktonic microbes, as well as immature and mature biofilms; and BIAKOS Antimicrobial Skin and Wound Irrigation Solution. In addition, it develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas. Read Less
Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydro...Read More
Frequently Asked Questions About Sanara Medtech Inc (SMTI) Stock
Based on ratings from 2 analysts Sanara Medtech Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 6 buy, sell and hold ratings.
Unfortunately we do not have enough data on SMTI's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for SMTI is USD 47.83 over the next 12 months. The maximum analyst target price is USD 51 while the minimum anlayst target price is USD 44.
Unfortunately we do not have enough data on SMTI's stock to indicate if its overvalued.
The last closing price of SMTI's stock was USD 29.20.
The most recent market capitalization for SMTI is USD 0.29B.
Based on targets from 2 analysts, the average taret price for SMTI is projected at USD 47.83 over the next 12 months.
This means that SMTI's stock price may go up by +65.80% over the next 12 months.
We can't find any ETFs which contains Sanara Medtech Inc's stock.
As per our most recent records Sanara Medtech Inc has 107 Employees.
Sanara Medtech Inc's registered address is 1200 Summit Avenue, Fort Worth, TX, United States, 76102.
You can get more information about it from Sanara Medtech Inc's website at https://sanaramedtech.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Sanara Medtech Inc (SMTI) Stock
Based on ratings from 2 analysts Sanara Medtech Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 6 buy, sell and hold ratings.
Unfortunately we do not have enough data on SMTI's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for SMTI is USD 47.83 over the next 12 months. The maximum analyst target price is USD 51 while the minimum anlayst target price is USD 44.
Unfortunately we do not have enough data on SMTI's stock to indicate if its overvalued.
The last closing price of SMTI's stock was USD 29.20.
The most recent market capitalization for SMTI is USD 0.29B.
Based on targets from 2 analysts, the average taret price for SMTI is projected at USD 47.83 over the next 12 months.
This means that SMTI's stock price may go up by +65.80% over the next 12 months.
We can't find any ETFs which contains Sanara Medtech Inc's stock.
As per our most recent records Sanara Medtech Inc has 107 Employees.
Sanara Medtech Inc's registered address is 1200 Summit Avenue, Fort Worth, TX, United States, 76102.
You can get more information about it from Sanara Medtech Inc's website at https://sanaramedtech.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for SMTI !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
